Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.
The post Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds appeared first on MedCity News.
